Study of Tislelizumab with Chemotherapy to Treat Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

What this Trial Is About

Researchers are evaluating the use of tislelizumab combined with chemotherapy as a conversion therapy for patients with initially unresectable locally advanced esophageal squamous cell carcinoma ESCC. This observational study includes 30 patients and aims to determine how many can undergo surgery after treatment. Secondary goals include assessing tumor response, pathological complete response, and safety. Participants will receive albumin-bound paclitaxel 260 mgm on day 1 every 3 weeks plus either cisplatin 75 mgm or carboplatin AUC 5, combined with tislelizumab 200 mg on day 2 every 3 weeks for 2 to 4 cycles. After treatment cycles, tumor staging is reassessed to decide if surgery is feasible, guided by a multidisciplinary team. The main study period lasts up to 12 weeks following treatment initiation. During the study, patients will undergo tumor assessments using standard criteria to measure response, with evaluations at approximately 6 to 16 weeks after starting treatment. Researchers will monitor adverse events from the first dose until 30 days after the last dose. Safety and survival follow-ups are included, and the overall focus is on conversion to surgery and treatment effects within this timeframe.

Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC